胰高糖素样肽-1受体激动剂特殊关注的三项安全性问题  

Three Special Safety Issues With Glucagon-Like peptide-1 Receptor Agonists

作　　者：董坤 余学锋 DONG Kun;YU Xue-feng(Department of Endocrinology,Tongji Hospital,Tongji Medical College Huazhong Univesity of Science&Technology,Wuhan Hubei 430030,China)

机构地区：[1]华中科技大学同济医学院附属同济医院内分泌科,湖北武汉430030

出　　处：《药品评价》2020年第S01期43-47,共5页Drug Evaluation

摘　　要：胰高糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1 RA)是一种兼顾降低血糖、减轻体重、改善并发症、低血糖发生率低等多方面功效的新型降糖药物,然而GLP-1 RA在临床上并未得到广泛的应用。究其原因可能是临床医生对GLP-1 RA应用的安全性有所顾虑。本文通过对GLP-1 RA在老年糖尿病患者、合并肾功能不全的糖尿病患者、合并肝功能不全的糖尿病患者中应用的安全性和有效性进行综述,旨在有助于临床医生在上述特殊人群中的应用。As a new antidiabetic drug,Glucagon-like peptide 1 receptor agonist(GLP-1 RA)has a variety of benefits in diabetic patients such as lowering blood glucose,reducing body weight,decreasing the incidence of hypoglycemia and other complications.However,GLP-1 RA has not been widely used in clinical practice.The reason may be due to that clinicians are concerned about the safety of the application of GLP-1RA.This paper reviews the safety and effectiveness of GLP-1 RA in elderly diabetic patients,diabetic patients with renal insufficiency as well as diabetic patients with liver dysfunction,which aims to help clinicians apply GLP-1 RA properly in the above special population.

关 键 词：胰高糖素样肽-1受体激动剂 老年 肝功能不全 肾功能不全 

分 类 号：R587.1[医药卫生—内分泌]